I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| plasmacytoid dendritic cell | 8 studies | 26% ± 6% | |
| hepatocyte | 6 studies | 71% ± 26% | |
| endothelial cell | 3 studies | 28% ± 9% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| plasmacytoid dendritic cell | 8 studies | 26% ± 6% | |
| hepatocyte | 6 studies | 71% ± 26% | |
| endothelial cell | 3 studies | 28% ± 9% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 3 studies | 54% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 86686.18 | 226 / 226 | 96% | 1176.93 | 390 / 406 |
| kidney | 100% | 6337.08 | 89 / 89 | 88% | 219.12 | 792 / 901 |
| prostate | 100% | 2459.81 | 245 / 245 | 75% | 23.61 | 376 / 502 |
| lung | 88% | 1521.02 | 510 / 578 | 54% | 18.51 | 619 / 1155 |
| pancreas | 93% | 555.95 | 305 / 328 | 38% | 13.35 | 68 / 178 |
| uterus | 98% | 896.97 | 166 / 170 | 21% | 5.91 | 98 / 459 |
| breast | 99% | 2078.09 | 453 / 459 | 17% | 5.03 | 186 / 1118 |
| bladder | 90% | 807.57 | 19 / 21 | 23% | 7.37 | 117 / 504 |
| intestine | 90% | 588.26 | 873 / 966 | 22% | 7.40 | 118 / 527 |
| ovary | 97% | 826.59 | 175 / 180 | 3% | 0.54 | 11 / 430 |
| spleen | 98% | 803.74 | 236 / 241 | 0% | 0 | 0 / 0 |
| esophagus | 83% | 375.65 | 1203 / 1445 | 14% | 4.35 | 25 / 183 |
| adipose | 95% | 1158.41 | 1138 / 1204 | 0% | 0 | 0 / 0 |
| thymus | 83% | 915.76 | 541 / 653 | 8% | 1.88 | 46 / 605 |
| blood vessel | 79% | 633.51 | 1061 / 1335 | 0% | 0 | 0 / 0 |
| skin | 69% | 397.15 | 1253 / 1809 | 6% | 1.09 | 28 / 472 |
| stomach | 53% | 330.20 | 190 / 359 | 19% | 7.64 | 54 / 286 |
| muscle | 54% | 248.12 | 433 / 803 | 0% | 0 | 0 / 0 |
| adrenal gland | 52% | 160.93 | 134 / 258 | 0% | 0 | 0 / 230 |
| lymph node | 0% | 0 | 0 / 0 | 52% | 10.34 | 15 / 29 |
| tonsil | 0% | 0 | 0 / 0 | 44% | 11.11 | 20 / 45 |
| heart | 31% | 123.73 | 267 / 861 | 0% | 0 | 0 / 0 |
| brain | 14% | 32.96 | 359 / 2642 | 5% | 0.82 | 33 / 705 |
| peripheral blood | 6% | 18.05 | 53 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 3% | 0.55 | 2 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0071636 | Biological process | positive regulation of transforming growth factor beta production |
| GO_0006953 | Biological process | acute-phase response |
| GO_0010951 | Biological process | negative regulation of endopeptidase activity |
| GO_0051496 | Biological process | positive regulation of stress fiber assembly |
| GO_0046330 | Biological process | positive regulation of JNK cascade |
| GO_0051918 | Biological process | negative regulation of fibrinolysis |
| GO_0010757 | Biological process | negative regulation of plasminogen activation |
| GO_0048661 | Biological process | positive regulation of smooth muscle cell proliferation |
| GO_0002034 | Biological process | maintenance of blood vessel diameter homeostasis by renin-angiotensin |
| GO_0042730 | Biological process | fibrinolysis |
| GO_0045597 | Biological process | positive regulation of cell differentiation |
| GO_0032967 | Biological process | positive regulation of collagen biosynthetic process |
| GO_2000049 | Biological process | positive regulation of cell-cell adhesion mediated by cadherin |
| GO_0030199 | Biological process | collagen fibril organization |
| GO_0048514 | Biological process | blood vessel morphogenesis |
| GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0062023 | Cellular component | collagen-containing extracellular matrix |
| GO_0072562 | Cellular component | blood microparticle |
| GO_0009986 | Cellular component | cell surface |
| GO_0031093 | Cellular component | platelet alpha granule lumen |
| GO_0005577 | Cellular component | fibrinogen complex |
| GO_0042803 | Molecular function | protein homodimerization activity |
| GO_0004866 | Molecular function | endopeptidase inhibitor activity |
| GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
| GO_0002020 | Molecular function | protease binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | SERPINF2 |
| Protein name | Alpha-2-antiplasmin Alpha-2-antiplasmin (Alpha-2-AP) (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Serpin F2) Plasmin inhibitor Serpin family F member 2 |
| Synonyms | AAP PLI |
| Description | FUNCTION: Serine protease inhibitor. The major targets of this inhibitor are plasmin and trypsin, but it also inactivates matriptase-3/TMPRSS7 and chymotrypsin. . |
| Accessions | ENST00000453066.6 [P08697-1] ENST00000622842.2 ENST00000453723.5 P08697 ENST00000615103.4 ENST00000632520.1 ENST00000324015.7 [P08697-1] C9JMH6 ENST00000453066 A0A0J9YY65 A0A0J9YWQ3 A0A3G2WJ85 C9JPV4 ENST00000382061.5 [P08697-1] ENST00000618883.3 ENST00000450523.6 [P08697-2] ENST00000631718.1 A0A0G2JPA8 |
